Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Sunitinib shows promise in treating metastatic renal cell cancer

A new study suggests that sunitinib is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options, according to an article in the June 7 issue of the Journal of the American Medical Association.

7 Jun 2006

Sunitinib malate drug shows significant benefits over standard treatment for advanced kidney cancer

According to a new study, the drug sunitinib malate (Sutent.) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC).

5 Jun 2006

Renal cell carcinoma in the pediatric population

While the incidence of renal cell carcinoma (RCC) is rising, it remains a relatively uncommon malignancy in the pediatric population, where it represents only 2-6% of solid renal malignancies.

16 May 2006

The management of renal cell carcinoma in the elderly

The median age of presentation for patients with renal cell carcinoma (RCC) is in the 6th decade of life, but urologists are not uncommonly confronted with an elderly patient with a renal mass seeking treatment.

10 May 2006

What is the best laparoscopic approach for laparoscopic radical nephrectomy?

Laparoscopic radical nephrectomy is rapidly becoming the gold standard as the surgical procedure of choice in patients with localized renal cell carcinoma.

10 May 2006

Circulating tumor cells in the bone marrow of patients with metastatic renal cell carcinoma may be prognostic of outcome

Circulating tumor cells in the blood and bone marrow have been examined in a variety of malignancies, including colorectal, breast, and head & neck cancers, to determine their prognostic significance.

8 May 2006

Underutilization of partial nephrectomy for localized renal cell carcinoma in the U.S.

In the past, the gold standard for the treatment of localized renal tumors has been radical nephrectomy. Over time however, experience with nephron sparing surgery and, now, laparoscopic approaches have demonstrated oncologic equipoise and may provide for an improved quality of life for patients as compared to those undergoing radical nephrectomy for localized renal masses.

31 Mar 2006

Thrombocytosis: A clinical marker of tumor aggressiveness in renal cell carcinoma

Molecular and serum markers of prognosis in renal cell carcinoma have remained elusive. In large part, tumor (TNM) stage, Fuhrman grade, and patient performance status have stood the test of time as the most valuable factors in predicting patient outcome following surgery.

15 Mar 2006

Therapy for metastatic renal cell carcinoma remains inadequate

The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the medical oncology community

9 Mar 2006

Is there any role for thalidomide as a monotherapy in the management of metastatic renal cell carcinoma?

Thalidomide remains an enigma in the treatment of metastatic renal cell carcinoma (RCC). Initial clinical trials suggested a benefit, but more recently, subsequent randomized trials studying thalidomide in combination with other agents such as interferon have demonstrated no added benefit.

8 Mar 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

Imatinib mesylate (Gleevec) may not be effective at treating kidney cancer

Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma -- the most aggressive kidney cancer.

22 Dec 2005

FDA approval sought for Pfizer's new cancer drug

Drug company Pfizer has announced it has submitted a New Drug Application (NDA) for its cancer drug Sutent, to the U.S. Food and Drug Administration (FDA).

11 Aug 2005

Radiofrequency ablation (RFA) is an effective, longlasting treatment for small kidney tumors in selected patients

Massachusetts General Hospital (MGH) researchers have shown that radiofrequency ablation (RFA) - a minimally invasive way of destroying tissue - is an effective, longlasting treatment for small kidney tumors in selected patients.

20 Jun 2005

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Key molecule helps identify renal cell carcinoma

Mayo Clinic researchers have discovered a key molecule that lets doctors identify one of the most aggressive types of kidney cancer. Patients with renal cell carcinoma who have higher levels of a molecule known as B7-H1 in their tumors are nearly five times more likely to die from the disease than patients with low levels or an absence of the molecule.

30 Nov 2004

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase."

10 Nov 2004